Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China
· Delayed Price · Currency is CNY 63.76
-0.27 (-0.42%)
Apr 29, 2026, 3:00 PM CST
SHA:688513 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 11,164 | 10,731 | 5,252 | 7,659 | 7,306 | 5,572 | Upgrade
|
| Market Cap Growth | 97.07% | 104.34% | -31.43% | 4.83% | 31.12% | -2.50% | Upgrade
|
| Enterprise Value | 9,722 | 9,298 | 4,010 | 6,419 | 6,112 | 3,987 | Upgrade
|
| Last Close Price | 64.03 | 61.55 | 29.84 | 42.48 | 40.11 | 30.07 | Upgrade
|
| PE Ratio | 40.51 | 37.78 | 22.05 | 33.81 | 29.64 | 23.97 | Upgrade
|
| Forward PE | 36.80 | 36.07 | 16.21 | 25.33 | 22.56 | - | Upgrade
|
| PS Ratio | 8.26 | 8.06 | 3.89 | 6.86 | 6.24 | 5.45 | Upgrade
|
| PB Ratio | 3.62 | 3.53 | 1.95 | 2.94 | 2.99 | 2.43 | Upgrade
|
| P/TBV Ratio | 4.04 | 3.97 | 1.97 | 2.98 | 3.03 | 2.47 | Upgrade
|
| P/FCF Ratio | 50.64 | 60.07 | 36.02 | 76.60 | - | - | Upgrade
|
| P/OCF Ratio | 35.83 | 40.51 | 19.95 | 27.83 | 48.09 | 37.75 | Upgrade
|
| EV/Sales Ratio | 7.19 | 6.98 | 2.97 | 5.75 | 5.22 | 3.90 | Upgrade
|
| EV/EBITDA Ratio | 29.32 | 26.94 | 16.05 | 28.47 | 28.33 | 23.72 | Upgrade
|
| EV/EBIT Ratio | 41.17 | 36.82 | 23.81 | 42.17 | 38.83 | 29.43 | Upgrade
|
| EV/FCF Ratio | 44.10 | 52.05 | 27.50 | 64.19 | - | - | Upgrade
|
| Debt / Equity Ratio | 0.03 | 0.05 | 0.04 | 0.09 | 0.04 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | 0.25 | 0.42 | 0.46 | 0.99 | 0.49 | 0.12 | Upgrade
|
| Debt / FCF Ratio | 0.37 | 0.82 | 0.78 | 2.24 | - | - | Upgrade
|
| Net Debt / Equity Ratio | -0.50 | -0.48 | -0.48 | -0.50 | -0.51 | -0.65 | Upgrade
|
| Net Debt / EBITDA Ratio | -4.64 | -4.25 | -5.24 | -5.76 | -5.76 | -8.83 | Upgrade
|
| Net Debt / FCF Ratio | -6.99 | -8.21 | -8.98 | -13.00 | 6.63 | 12.11 | Upgrade
|
| Asset Turnover | 0.37 | 0.37 | 0.40 | 0.35 | 0.40 | 0.39 | Upgrade
|
| Inventory Turnover | 1.48 | 1.57 | 1.97 | 1.50 | 1.63 | 1.56 | Upgrade
|
| Quick Ratio | 3.32 | 3.03 | 2.87 | 2.57 | 2.89 | 3.77 | Upgrade
|
| Current Ratio | 3.82 | 3.45 | 3.23 | 2.85 | 3.23 | 4.11 | Upgrade
|
| Return on Equity (ROE) | 8.76% | 9.54% | 8.99% | 8.98% | 10.41% | 10.60% | Upgrade
|
| Return on Assets (ROA) | 4.08% | 4.39% | 3.12% | 2.99% | 3.40% | 3.19% | Upgrade
|
| Return on Invested Capital (ROIC) | 13.64% | 15.58% | 11.80% | 11.39% | 14.74% | 19.36% | Upgrade
|
| Return on Capital Employed (ROCE) | 7.30% | 7.90% | 6.00% | 5.70% | 6.30% | 5.80% | Upgrade
|
| Earnings Yield | 2.46% | 2.65% | 4.54% | 2.96% | 3.37% | 4.17% | Upgrade
|
| FCF Yield | 1.97% | 1.67% | 2.78% | 1.31% | -2.56% | -2.20% | Upgrade
|
| Dividend Yield | 0.65% | - | 1.44% | 0.93% | 0.95% | 1.76% | Upgrade
|
| Payout Ratio | 27.90% | 27.03% | 31.11% | 31.37% | 38.96% | 15.66% | Upgrade
|
| Buyback Yield / Dilution | 1.46% | 0.52% | 1.04% | -0.14% | -0.37% | -19.70% | Upgrade
|
| Total Shareholder Return | 2.12% | 0.52% | 2.48% | 0.79% | 0.58% | -17.94% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.